二线脂质体伊立替康联合S-1对比联合5-FU/亚叶酸钙治疗转移性胰腺癌:I/II期随机NABAN试验
国际多中心开放标签随机I/II期优效性试验纳入120例既往吉西他滨治疗失败的转移性胰腺癌患者,随机接受nal-IRI联合S-1或nal-IRI联合5-FU/LV治疗。主要终点PFS在两组分别为2.2个月和3.3个月(HR 1.27,95%CI 0.84-1.91,p=0.26),OS分别为6.0个月和9.1个月(HR 1.47,95%CI 0.99-2.17,p=0.054),联合S-1未显示优效。
要点
- nal-IRI联合S-1对比联合5-FU/LV未改善PFS(2.2 vs 3.3个月,HR 1.27,p=0.26)。
- 两组OS无显著差异(6.0 vs 9.1个月,HR 1.47,p=0.054)。
- S-1组最常见3-4级不良事件为腹泻(13.8%)和恶心(10.3%)。
核心结论
- 在吉西他滨治疗失败的转移性胰腺癌患者中,二线nal-IRI联合S-1相比nal-IRI联合5-FU/LV未能改善PFS和OS。
研究设计与样本
- 国际多中心开放标签随机I/II期优效性试验,纳入120例既往吉西他滨治疗的胰腺腺癌患者,随机分配至S-1组(n=61)或5-FU组(n=59),3例因不符合资格被排除。
主要发现
- 中位PFS在S-1组为2.2个月,5-FU组为3.3个月(HR 1.27;95%CI 0.84-1.91,p=0.26)。
- 中位OS在S-1组为6.0个月,5-FU组为9.1个月(HR 1.47;95%CI 0.99-2.17,p=0.054)。
- S-1组最常见的3-4级不良事件为腹泻(13.8%)和恶心(10.3%);5-FU组为腹泻(14.0%)、乏力(7.0%)和黏膜炎(7.0%)。
临床怎么用
- 对于既往吉西他滨治疗失败的转移性胰腺癌,二线nal-IRI联合5-FU/LV仍是参考方案,联合S-1未显示优效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study aimed to determine the optimal second-line treatment strategy in patients with metastatic pancreatic cancer, hypothesizing that liposomal irinotecan (nal-IRI) combined with S-1 would be superior to nal-IRI with 5-fluorouracil (5-FU)/leucovorin (LV). METHODS: This was an international, multi-center, open-label, randomized phase I/II superiority trial. Patients with pancreatic adenocarcinoma, previously treated with gemcitabine-based treatment, were enrolled. Patients were randomly allocated to receive either nal-IRI plus S-1 (S-1 arm) or nal-IRI plus 5-FU/LV (5-FU arm). The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), (serious) adverse events (SAEs), response rate, and health-related quality of life. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using a Cox model. This trial is registered with ClinicalTrials.gov (NCT03986294) and is completed. RESULTS: Between November 10, 2021 and May 23, 2023, 120 patients were randomized to the S-1 arm (n = 61) or the 5-FU arm (n = 59). Three patients were excluded due to ineligibility. Median PFS was 2.2 months in the S-1 arm vs. 3.3 months in the 5-FU arm (HR 1.27; 95% CI 0.84-1.91, p = 0.26). Median OS was 6.0 months in the S-1 arm vs. 9.1 months in the 5-FU arm (HR 1.47; 95% CI 0.99-2.17, p = 0.054). The most common grade 3-4 AEs were diarrhea (13.8%) and nausea (10.3%) in the S-1 arm, and diarrhea (14.0%), asthenia and mucositis (both 7.0%) in the 5-FU arm. CONCLUSION: Second-line treatment with nal-IRI plus S-1 did not improve PFS and OS compared to nal-IRI plus 5-FU/LV in patients with metastatic pancreatic cancer following first-line gemcitabine-based chemotherapy.
引用
- Gehrels AM, Pijnappel EN, van Daalen EH, et al. Second-line liposomal irinotecan plus S-1 vs. liposomal irinotecan plus 5-fluorouracil in metastatic pancreatic cancer: The phase I/II randomized NAPAN trial. Eur J Cancer. 2026. PMID: 41921365. doi:10.1016/j.ejca.2026.116683
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。